Use of Biomarker Based on Human Basophil Syk Expression to Predict the Clinical Efficacy of Omalizumab Treatment in Allergic Asthmatics

Use of Biomarker Based on Human Basophil Syk Expression to Predict the Clinical Efficacy of Omalizumab Treatment in Allergic Asthmatics

Conclusions This study suggests that changes in syk expression and therefore the functionality of human basophils may provide a predictor of successful treatment of asthmatics with omalizumab. Since the change in syk expression is related to starting syk, it is possible that baseline basophil syk or...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2017-02, Vol.139 (2), p.AB167-AB167
Hauptverfasser: MacGlashan, Donald, MD, PhD, Saini, Sarbjit Singh, MD, FAAAAI
Format: Artikel
Sprache:eng
Schlagworte:
Allergies
Allergy and Immunology
Asthma
Histamine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Conclusions This study suggests that changes in syk expression and therefore the functionality of human basophils may provide a predictor of successful treatment of asthmatics with omalizumab. Since the change in syk expression is related to starting syk, it is possible that baseline basophil syk or histamine release might be a bio-marker of successful treatment with omalizumab.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2016.12.548